Document Detail


Molecular pathology of prostate cancer revealed by next-generation sequencing: opportunities for genome-based personalized therapy.
MedLine Citation:
PMID:  23385974     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE OF REVIEW: This article reviews recently identified genomic mutations in prostate cancer.
RECENT FINDINGS: Advanced sequencing technologies have made it possible to obtain large amounts of data on genomes and transcriptomes of cancers. Such technologies have been used to sequence prostate cancer of different stages, from treatment-naive cancers, to advanced, castration-resistant cancers to the aggressive small cell neuroendocrine carcinomas. For each category of prostate cancer, distinct and overlapping DNA sequence alterations were discovered, including point mutations, small insertions or deletions, copy number changes and chromosomal rearrangements. There appears to be a stepwise increase in genomic alterations from low risk to high risk to advanced cancers.
SUMMARY: These novel findings have significantly increased our knowledge of the genetic basis of human prostate cancer and the molecular mechanisms responsible for disease progression and treatment resistance. Some of the lesions are potential therapeutic targets. Studies along this direction will eventually make it possible to design personalized management plans for individual patients.
Authors:
Jiaoti Huang; Jason K Wang; Yin Sun
Related Documents :
23411384 - Using multigene tests to select treatment for early-stage breast cancer.
16431004 - Cancer in the mass print media: fear, uncertainty and the medical model.
16518444 - The case for development of a new test of health literacy.
24141004 - Outcomes of screening endometrial cancer patients for lynch syndrome by patient-adminis...
19622104 - Prostaglandin e2, wnt, and bmp in gastric tumor mouse models.
6501374 - Development of the iron-cored electromagnet for the treatment of non-union and delayed ...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Review    
Journal Detail:
Title:  Current opinion in urology     Volume:  23     ISSN:  1473-6586     ISO Abbreviation:  Curr Opin Urol     Publication Date:  2013 May 
Date Detail:
Created Date:  2013-04-03     Completed Date:  2013-09-24     Revised Date:  2014-08-04    
Medline Journal Info:
Nlm Unique ID:  9200621     Medline TA:  Curr Opin Urol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  189-93     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
DNA Mutational Analysis*
Gene Expression Profiling*
Genetic Predisposition to Disease
Genomics / methods*
High-Throughput Nucleotide Sequencing*
Humans
Individualized Medicine*
Male
Mutation*
Phenotype
Predictive Value of Tests
Prognosis
Prostatic Neoplasms / genetics*,  pathology,  therapy
Risk Assessment
Risk Factors
Grant Support
ID/Acronym/Agency:
1R01CA158627-01/CA/NCI NIH HHS; R01 CA172603/CA/NCI NIH HHS
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The promise of heat shock protein inhibitors in the treatment of castration resistant prostate cance...
Next Document:  Lessons from in-vivo models of castration-resistant prostate cancer.